A single administration of the hallucinogen, 4-acetoxy-dimethyltryptamine, prevents the shift to a drug-dependent state and the expression of withdrawal aversions in rodents.
Despite several studies suggesting the therapeutic use of 5-hydroxytryptamine receptors type 2A (5-HT